Irbesartan + Hidroclorotiazida Krka

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartan + Hidroclorotiazida Krka, are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for oral use. They treat hypertension in adult patients by lowering blood pressure through vascular relaxation and fluid reduction.

GNH USA supplies Irbesartan + Hidroclorotiazida Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets, with a focus on patient safety and therapeutic efficacy.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by elevated arterial pressure. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Diastolic hypertension: helps achieve recommended diastolic pressure goals. - Hypertension requiring combination therapy: provides dual mechanism for improved blood pressure control.

Common and serious adverse reactions have been reported with Irbesartan/Hydrochlorothiazide therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling of tiredness or reduced energy. - Increased urination: due to diuretic effect. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated potassium levels that may affect heart rhythm. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Blood dyscrasias: rare blood cell abnormalities.

Before initiating Irbesartan/Hydrochlorothiazide, clinicians should consider several precautionary measures. - Renal function monitoring: assess serum creatinine and eGFR periodically. - Electrolyte assessment: check potassium and sodium levels, especially in patients on other diuretics. - Use in hepatic impairment: exercise caution in severe liver disease. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effects on blood pressure and potassium. - Lithium: increased lithium levels leading to toxicity. - NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance blood pressure lowering, requiring dose adjustment. - Calcium channel blockers: possible additive hypotensive effect. - Antidiabetic agents: diuretic may affect glucose control. - Antihypertensive combinations: monitor for excessive hypotension. - Thiazide‑type diuretics: cumulative electrolyte disturbances.